PharmaEssentia Corporation
6446
주식 순위
#1453
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
주가
$35.96
시가총액
$14.87B
변동 (1일)
-0.85%
변동 (1년)
138.77%
국가
TW
거래 PharmaEssentia Corporation (6446)
카테고리
Healthcare
PharmaEssentia Corporation (6446)의 주가 이력
최고 종가: $37.51 (2026-10-01 기준)
최저 종가: $4.95 (2014-03-01 기준)
최저 종가: $4.95 (2014-03-01 기준)
PharmaEssentia Corporation의 주가 이력 (2014 ~ 2026)
연간 주가 성과
| 연도 | 성과 |
|---|---|
| 2026 (TTM) | 78.21% |
| 2025 | -1.54% |
| 2024 | 65.30% |
| 2023 | -34.57% |
| 2022 | 52.79% |
| 2021 | 220.53% |
| 2020 | 2.39% |
| 2019 | -41.63% |
| 2018 | 21.23% |
| 2017 | -8.25% |
| 2016 | -3.31% |
| 2015 | 21.68% |
| 2014 | 0.00% |
유사 기업 또는 경쟁사의 주가
| 회사 | 주가 | 변동률 1년% | 국가 |
|---|---|---|---|
| $171.67 | - |
DE
|
|
| $161.15 | 20.52% |
DE
|
|
| $40.45 | 43.11% |
JP
|
|
| $212.49 | 24.09% |
CH
|
|
| $18.48 | -3.78% |
IN
|
